Oncogenesis, although led by proven medical device and diagnostic professionals that have built successful businesses and products in these fields, the company strategy from day one is to identify and utilize strategic partners and license in where applicable related technologies to assure lower costs of development in a shorter period and provide better outcomes.
Peter Gombrich is a serial entrepreneur having successfully founded three medical device companies. Peter founded OncoGenesis (previously CerMed) in 2008, and has been working in the field of molecular diagnostics for women’s health for over 10 years. Previously, Peter founded and led Accumed/Molecular Diagnostics, a cytopathic laboratory products company, which he took public. He founded and served as CEO of CliniCom, a provider of bedside clinical information, which was later acquired by McKesson. Prior to these experiences, Peter co-founded St. Jude Medical, the largest heart valve company in the world. Peter holds a BSc degree in Electrical Engineering from the University of Denver, Colorado, and an MBA from the University of Denver, Colorado.
Paul Vichi, Ph.D. Over 25 years experience in academia and industry related to pharmacology, oncology, biomedical technologies and materials sciences, including VP and Chief Scientific Officer for MATRX Pharmaceuticals, Inc., Chief Development and Technical Officer, and founding member at Cermed Corporation, the predecessor to OncoGenesis; and Senior Scientist for R&D at Diffraction, LTD., and Creative MicroSystems Corp, which specialize in microfabrication and nanostructuring for prototype microfluidic devices, and diffractive optical elements. A former faculty member at the University of Vermont (UVM). Dr. Vichi earned a Ph.D. in Cellular & Molecular Biology from the UVM and completed postdoctoral fellowships in Molecular Physiology and Biophysics at UVM, and Cancer Biology at the Institut Genetique, et de Biologie, Moleculaire et Cellulaire (IGBMC), Strasbourg, France.